Inventiva company profile

IVA · Euronext Paris · EUR

Compare Inventiva
€2.94Change from previous close: −7.27%Absolute change: −€0.23

Close · November 20, 2026

Company profile

Inventiva has 87 employees and is headquartered in Daix, France.

Patients with metabolic dysfunction-associated steatohepatitis, known as MASH, and with mucopolysaccharidoses are among the groups this company develops treatments for, in France and in other countries. Its activity centres on orally administered small molecules aimed at MASH and other diseases, and its research pipeline is at clinical and pre-clinical stages. Lanifibranor, a peroxisome proliferator-activated receptor agonist, is in the NATiV3 Phase 3 trial in adult patients with MASH. Odiparcil targets mucopolysaccharidoses, and a pre-clinical TGF-β program addresses idiopathic pulmonary fibrosis.

In the fiscal year ended 31 December 2025, revenue was 6.8 million euros, down 52.0% from the previous year, while the net loss reached 354.1 million euros. The accounts cover the twelve months to that date. The company employed 87 people and is headquartered in Daix, France; it was incorporated in 2011.

Company facts

Industry
Biotechnology
Country
France
Headquarters
50 rue de Dijon, 21121, Daix
Employees
87
Chief executive
Andrew Obenshain
Founded
2011
Fiscal year
January - December
Listing
IVA · Euronext Paris
Currency
EUR
ISIN
FR0013233012

Inventiva and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
InventivaIVAFrance$890.8M87-5,980.9%—
Pharming GroupPHARMNetherlands$841.25M40712.8%36.1
PhilogenPHILItaly$905.96M23079.1%3.67
Basilea PharmaceuticaBSLNSwitzerland$1.07B20024.2%18.1
GubraGUBRADenmark$730.02M330-73.1%—
Pharma MarPHMSpain$1.1B50521.3%14.7

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Inventiva with its competitors